Wayne

Wayne Biotechnology is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, focused on the discovery and development of innovative therapies for metabolic diseases, obesity, oncology, and neurological disorders. Founded in 2020 and based in the Zhangjiang High-Tech Park, the company utilizes an integrated platform to advance a pipeline of small molecule candidates, most notably next-generation oral GLP-1 receptor agonists. Its lead program, WBD156, is an oral small molecule GLP-1RA currently in Phase 1 clinical trials for the treatment of obesity and metabolic syndrome. In addition to its internal drug development efforts, Wayne Biotechnology provides specialized research services, such as phospho-antibody arrays and cytokine analysis, to support global biomedical research.